19.00
-0.52%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Innoviva
From its filings with the US Securities and Exchange Commission
Innoviva is based in Burlingame, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INVA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $411.3m and net income of $271.2m. At that date it held total assets of $1.64bn and shareholders' equity of $1.17bn.
Innoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic healthcare assets.
Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/vilanterol, “FF/VI”) and ANORO® ELLIPTA® (umeclidinium bromide/vilanterol, “UMEC/VI”). Under the Long-Acting Beta-2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO® ELLIPTA®, which tier upward at a range from 6.5% to 10%.
In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc., a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies through our portfolio approach.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Oct 2004
- Employees
- 159
- Website
- inva.com ↗
- Head office
- 1350 OLD BAYSHORE HIGHWAY, BURLINGAME, CA, 94010
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Mark DipaoloChairman of the Board$380,292
- Mr. Pavel RaifeldChief Executive Officer$2.7m
- Mr. Stephen BassoChief Financial Officer$1.0m
- Ms. Marianne ZhenChief Accounting Officer$967,319
- Dr. Sarah SchlesingerLead Independent Director$392,032
- Dr. Odysseas KostasDirector$341,162
- Mr. Jules HaimovitzIndependent Director$401,162
- Mr. Derek SmallIndependent Director$481,902
- Dr. Sapna SrivastavaIndependent Director$376,162
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 4
- Social
- 47
- Governance
- 37
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innoviva Inc has a strong portfolio of patented respiratory products, providing a competitive advantage in the market. This allows the company to maintain a significant market share and generate substantial revenue.
- The company has a highly experienced and skilled research and development team, constantly exploring innovative solutions to address respiratory diseases. This expertise enables Innoviva to stay ahead of its competitors and develop cutting-edge products.
Weaknesses
- Innoviva heavily relies on partnerships for the commercialization of its products, which can result in limited control over pricing and distribution. This dependence on partners may impact the company's profitability.
- The company's product pipeline is relatively limited, with a focus on respiratory medications. This narrow focus may limit Innoviva's ability to explore other profitable therapeutic areas.
Opportunities
- The global respiratory therapeutic market is expected to grow significantly in the coming years, presenting a tremendous opportunity for Innoviva to expand its market share and generate increased revenue.
- Innoviva can explore strategic partnerships or acquisitions to diversify its product offerings and enter new therapeutic areas. This would allow the company to tap into additional revenue streams and enhance its competitive position.
Threats
- Intense competition in the respiratory therapeutic market poses a threat to Innoviva's market share and pricing power. Competitors may introduce alternative products or pricing strategies that could result in reduced profitability.
- The regulatory environment surrounding respiratory medications is subject to changes and uncertainties. Changes in regulations or the introduction of new requirements may impact Innoviva's ability to bring products to market and generate revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.